KN38-7271: Phase I data

In a double-blind, placebo-controlled Phase I trial in 18 healthy volunteers, 24-hour infusions of 1.5 and 3 mg of KN38-7271 were safe and well tolerated. The half-life was 9-15 hours for the low dose...